Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. KEGG DRUG DrugBank 薬物名(臨床試験情報から抽出) KEGG GENES KEGG PATHWAY 指定難病告示番号
1 Riboflavin 💬 1件: Riboflavin2件: Riboflavin; Vitamin B2; --7件: 38, 46, 96, 97, 162, 168, 265 💬
2 Didanosine 💬 1件: Didanosine1件: Didanosine; --2件: 25, 265 💬
3 Lamivudine 💬 1件: Lamivudine4件: COMBIVIR; Epivir; Lamivudine; Triumeq; --7件: 2, 26, 42, 46, 135, 265, 325 💬
4 Zidovudine 💬 1件: Zidovudine3件: COMBIVIR; Retrovir; Zidovudine; --6件: 25, 26, 135, 265, 325, 331 💬
5 Ritonavir 💬 1件: Ritonavir2件: Norvir; Ritonavir; --3件: 2, 86, 265 💬
6 Saquinavir 💬 1件: Saquinavir1件: Saquinavir; --2件: 86, 265 💬
7 Simvastatin 💬 1件: Simvastatin3件: Simvastatin; Simvastatina; Simvastatine; 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
8 Nevirapine 💬 1件: Nevirapine1件: Nevirapine; --1件: 265 💬
9 Stavudine 💬 1件: Stavudine1件: Stavudine; --1件: 265 💬
10 Pyrimethamine 💬 1件: Pyrimethamine2件: Daraprim; Pyrimethamine; --4件: 2, 4, 19, 65 💬
11 Caffeine 💬 1件: Caffeine1件: Caffeine; 11件: ADORA1,
ADORA2A,
PDE1B,
PDE2A,
PDE3A,
PDE3B,
PDE4A,
PDE4B,
PDE4C,
PDE4D,
PDE5A 💬
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 2, 6, 21, 46, 78, 96, 97, 265 💬
12 Fenofibrate 💬 1件: Fenofibrate1件: Fenofibrate; 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬6件: 8, 79, 93, 94, 97, 265 💬
13 Amprenavir 💬 1件: Amprenavir1件: Amprenavir; --1件: 265 💬
14 Efavirenz 💬 1件: Efavirenz2件: Efavirenz; SUSTIVA; --1件: 265 💬
15 Emtricitabine 💬 1件: Emtricitabine2件: Emtricitabine; TRUVADA; --4件: 25, 93, 265, 325 💬
16 Lopinavir 💬 1件: Lopinavir2件: Kaletra; Lopinavir; --2件: 93, 265 💬
17 Caffeine hydrate 💬 1件: Caffeine1件: Caffeine; 11件: ADORA1,
ADORA2A,
PDE1B,
PDE2A,
PDE3A,
PDE3B,
PDE4A,
PDE4B,
PDE4C,
PDE4D,
PDE5A 💬
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 2, 6, 21, 46, 78, 96, 97, 265 💬
18 Levocarnitine 💬 1件: Levocarnitine4件: Carnitine; L-Carnitine; LEVOCARNITINE; Xyzal; --11件: 3, 5, 13, 53, 58, 86, 96, 97, 265, 298, 316 💬
19 Enfuvirtide 💬 1件: Enfuvirtide1件: Enfuvirtide; --2件: 25, 265 💬
20 Mecasermin 💬 1件: Mecasermin3件: INCRELEX; Mecasermin; MECASERMINA; 2件: GHR,
IGF1R 💬
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬6件: 65, 78, 96, 168, 265, 299 💬
21 Indinavir 💬 1件: Indinavir1件: Indinavir; --1件: 265 💬
22 Metformin 💬 1件: Metformin5件: Metformin; Metformin HCl; Metformin Hydrochloride; METFORMINA; Metformine; 2件: PRKAA1,
PRKAA2 💬
20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬25件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
23 Metreleptin 💬 1件: Metreleptin3件: METRELEPTIN; Myalept; R-metHuLeptin; 1件: LEPR 💬6件: AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease 💬1件: 265 💬
24 Pegvisomant 💬 1件: Pegvisomant1件: Pegvisomant; 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬2件: 78, 265 💬
25 Tenofovir 💬 1件: Tenofovir1件: Tenofovir; --6件: 2, 13, 25, 93, 265, 325 💬
26 Tesamorelin 💬 1件: Tesamorelin2件: GHRH; Tesamorelin; 1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬2件: 78, 265 💬
27 Raltegravir 💬 1件: Raltegravir2件: ISENTRESS; Raltegravir; --4件: 13, 26, 93, 265 💬
28 Abacavir 💬 1件: Abacavir4件: Abacavir; Abacavir sulfate; Triumeq; Ziagen; --4件: 2, 135, 265, 325 💬
29 Acipimox 💬 1件: Acipimox1件: Acipimox; --2件: 78, 265 💬
30 Atazanavir 💬 1件: Atazanavir2件: Atazanavir; Reyataz; --1件: 265 💬
31 Atorvastatin 💬 1件: Atorvastatin3件: Atorvastatin; Atorvastatin calcium; Lipitor; 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
32 Diosmin 💬 1件: Diosmin1件: DIOSMIN; --3件: 46, 97, 265 💬
33 Nelfinavir 💬 1件: Nelfinavir1件: Nelfinavir; --3件: 49, 265, 331 💬
34 Pioglitazone 💬 1件: Pioglitazone1件: Pioglitazone; 1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
35 Pravastatin 💬 1件: Pravastatin2件: Pravastatin; Pravastatin sodium; 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 💬
36 Rosiglitazone 💬 1件: Rosiglitazone2件: Rosiglitazone; Rosiglitazone maleate; 1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬5件: 46, 75, 97, 222, 265 💬
37 Thiamine 💬 1件: Thiamine2件: THIAMINE; Vitamin B1; --4件: 8, 93, 145, 265 💬
38 Tipranavir 💬 1件: Tipranavir1件: Tipranavir; --1件: 265 💬
39 Obeticholic acid 💬 1件: Obeticholic acid4件: 6-ECDCA; 6-ethylchenodeoxycholic acid; OBETICHOLIC ACID; Ocaliva; 1件: NR1H4 💬1件: Bile secretion 💬3件: 93, 265, 296 💬
40 Dolutegravir 💬 1件: Dolutegravir2件: Dolutegravir; Triumeq; --2件: 2, 265 💬
41 Baricitinib 💬 1件: Baricitinib2件: Baricitinib; Olumiant; 2件: JAK1,
JAK2 💬
35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
42 Doravirine 💬 1件: Doravirine1件: Doravirine; --1件: 265 💬
43 Cholic acid 💬 1件: Cholic Acid1件: Cholic Acid; 1件: NR1H4 💬1件: Bile secretion 💬4件: 20, 234, 265, 310 💬
44 Volanesorsen 💬 1件: Volanesorsen1件: Volanesorsen; 1件: APOC3 💬2件: Cholesterol metabolism, PPAR signaling pathway 💬1件: 265 💬
45 Setmelanotide 💬 1件: Setmelanotide1件: Setmelanotide; 1件: MC4R 💬1件: Neuroactive ligand-receptor interaction 💬2件: 202, 265 💬